The U.K.'s Medical Research Council and the Wellcome Trust will put $20.5 million toward the development of a database of induced pluripotent stem cells, to be called the Human Induced Pluripotent Stem Cell Initiative. The initiative will aim to produce iPS cells from healthy volunteers and from patient groups for use in genetic disease studies. The database will function as a "comprehensive resource for investigating how genetic variation impacts on cell behavior and how diseases linked to a specific genetic defect can result in a broad spectrum of clinical abnormalities," according to the Wellcome Trust.